Form 8-K - Current report:
SEC Accession No. 0000950170-25-063523
Filing Date
2025-05-05
Accepted
2025-05-05 16:05:08
Documents
13
Period of Report
2025-05-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K bmea-20250505.htm   iXBRL 8-K 43544
2 EX-99.1 bmea-ex99_1.htm EX-99.1 112834
3 GRAPHIC img268133598_0.jpg GRAPHIC 36830
  Complete submission text file 0000950170-25-063523.txt   331275

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT bmea-20250505.xsd EX-101.SCH 24869
15 EXTRACTED XBRL INSTANCE DOCUMENT bmea-20250505_htm.xml XML 4704
Mailing Address 900 MIDDLEFIELD ROAD 4TH FLOOR REDWOOD CITY CA 94063
Business Address 900 MIDDLEFIELD ROAD 4TH FLOOR REDWOOD CITY CA 94063 (650) 980-9099
Biomea Fusion, Inc. (Filer) CIK: 0001840439 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40335 | Film No.: 25912856
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)